Recursion's AI-Discovered Drug Shows Promise in Rare Genetic Cancer

Recursion Pharmaceuticals announced on Monday that its AI-discovered drug REC-4881 achieved measurable success in treating familial adenomatous polyposis (FAP), a rare genetic condition that causes hundreds of polyps in the colon and dramatically increases colorectal cancer risk. The results mark the first clinical validation of Recursion's AI platform after moving from laboratory discovery to human patients.

In the Phase 1b/2 TUPELO trial, 9 out of 11 patients maintained a durable reduction in total polyp burden, with a median reduction of 53% twelve weeks after stopping therapy. That durability matters. Previous treatments temporarily suppress polyps but require ongoing administration or surgery. This drug appears to create lasting remission.​

"This is the first clinical validation of Recursion's AI platform, where we garnered unbiased insights to know that this molecule could work in this disease and now proving it in patients," said Najat Khan, incoming CEO of Recursion.

The stock market agreed. Recursion shares rose 6% in premarket trading on the news. But the real significance is about what this result means for drug discovery, AI development, and a disease that currently offers only one real treatment. Surgical removal of the colon.